Sarah Bhatt

Sarah Bhatt has contributed to clinical validation and harmonization efforts for tumor mutational burden as a predictive biomarker for checkpoint immunotherapy benefit, examining its utility as a pan-tumor biomarker and in specific tumor types. Her research has examined the KEYNOTE-158 basket trial data supporting pembrolizumab accelerated approval for TMB-high unresectable or metastatic solid tumors, analyzing the variable predictive utility of TMB across the 10 tumor types included. She has investigated TMB measurement harmonization including the correlation between whole exome sequencing-based TMB and panel-based TMB scores across different comprehensive genomic profiling assays used clinically. Her translational work on combining TMB with other immune biomarkers including TIL levels and gene expression signatures for multi-marker IO predictive models has contributed to moving beyond single biomarker approaches in IO patient selection.